Kronos Bio Q1 net loss $30M, cash $152M into H2 2026; restructuring charges $12.8M

Kronos Bio, Inc.

2024-Q1 EPS reported -$0.50 revenue$2,520,000

Net loss of $30.0M ($0.50/share) includes $7.7M stock-based comp; R&D $14.2M, G&A $7.5M.
Impairment of long-lived assets $6.6M; restructuring expense $6.2M (includes $4.4M stock-based comp).
Cash, equivalents and investments $152.0M, sufficient into second half of 2026.
KB-0742 Phase 1/2 update to be presented at ASCO June 1; expansion cohorts on track Q3 2024.
KB-9558 IND-enabling studies to complete by end 2024; first-in-human expected H1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kronos Bio, Inc. reported the quarter ended March 31, 2024 results: net income $30.0 million, or $0.50 per share, EPS $0.50 per share.

Period: the quarter ended March 31, 2024
Net income: $30.0 million, or $0.50 per share
EPS: $0.50 per share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2024 was $30.0 million, or $0.50 per share, including non-cash stock-based compensation expense of $7.7 million.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001741830-24-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.